This report aims to provide detailed insights into the global Infection Control Market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
Expected Revenue Growth:

The global infection control market is projected to reach USD 52.7 billion by 2026 from USD 44.7 billion in 2021, at a CAGR of 3.4% during the forecast period.

Growth in the infection control market can largely be attributed to factors such as the high incidence of hospital-acquired infections; the increasing number of surgical procedures; the growing geriatric population and increasing incidence of chronic diseases; the growing focus on food sterilization and disinfection; technological advancements in sterilization equipment; and the increasing outsourcing of sterilization services among pharmaceutical companies, hospitals, and medical device manufacturers. The growing number of medical device and pharmaceutical companies in emerging economies, increasing use of E-beam sterilization, re-introduction of ethylene oxide sterilization, and outsourcing operations to emerging countries with an improving healthcare sector will also support the growth of the market in the coming years. Currently, with the surge in cases of COVID-19, there is an increasing focus on personal hygiene and increasing production of medical nonwovens and single-use products, such as face masks and gloves. This, in turn, is expected to propel market growth in the next two years.


Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1084
Infection Control Market Dynamics

Driver: High incidence of hospital-acquired infections (HAIs)
Hospital-acquired infections (HAIs) are nosocomial infections that occur during a patient’s stay at hospitals and related facilities and are not observed at the time of admission. They are a major cause of morbidity and mortality worldwide. These infections include central line-associated bloodstream infections, surgical-site infections, catheter-associated urinary tract infections, hospital-acquired pneumonia, ventilator-associated pneumonia, and Clostridium difficile infections. The most common bacteria associated with HAIs include C. difficile, MRSA, Klebsiella, E. coli, Enterococcus, and the Pseudomonas species. Using infected medical devices during diagnostic and therapeutic procedures is a major cause of HAIs. According to the CDC, up to 1.7 million hospitalized patients in the US annually acquire healthcare-associated infections (HCAIs) while being treated for other health issues, and more than 98,000 of these patients (one in 17) die due to HCAIs. 32% of all HAIs in the country are urinary tract infections, 22% are surgical-site infections, 15% are lung (pneumonia) infections, and 14% are bloodstream infections. This is expected to boost the demand for sterilization and disinfectant products. The incidence of HAIs is mainly dependent on the patient’s immune status, infection control practices, and the prevalence of various infectious agents in the healthcare facility. Other factors include longer hospital stays, immunosuppression, older age, and stays in intensive care units. Around 20% of such infections occur in ICUs. The major pathogens causing HAIs include C. difficile, Staphylococcus aureus, Klebsiella, and Escherichia coli. The outbreak of COVID-19 and the growing cases of community transmission infections identified in healthcare personnel (HCP) have led to the implementation of guidelines for infection control by various government bodies across the globe. Considering such developments, the demand for infection control practices such as the proper use of sterilization and disinfectant products is expected to increase in healthcare facilities across the globe in the coming years.

Restraint: Adverse effects of chemical disinfectants
Most of the chemical disinfectants currently available in the market have toxic properties. For example, sodium hypochlorite is an effective treatment against blood-borne pathogens but is also highly corrosive and a respiratory irritant, which makes it dangerous for cleaning personnel and building occupants and toxic when released into the environment. The improper use of these disinfectants can cause environmental hazards and be harmful to patients exposed to them. Disinfectants sold in the US need to be registered with the Environmental Protection Agency (EPA), which classifies these solutions as pesticides; they are regulated under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). There is no green certificate currently available for disinfectants in the market. Due to the growing end-user population demanding a greener solution, the use of disinfectants is becoming limited, with their use being restricted to limited non-critical items and in lower amounts. Manufacturers are now being forced to develop newer, greener alternatives that are less corrosive to the human eyes, such as butyl-free, pH-neutral quaternary, and hydrogen peroxide-based disinfectants. In line with this, in 2018, Clorox Healthcare launched the new Clorox Healthcare Versa-Sure Cleaner Disinfectant Wipes that are alcohol-free.

Opportunity: Increasing use of E-beam sterilization
Electron-beam irradiation, also called beta irradiation, is a technique used commonly to sterilize pharmaceutical packaging products and medical devices. It operates by directing a continuous flow of electrons through the articles being sterilized. It is generally used for low- to medium-density products but not a good fit for extremely dense materials. This sterilization has the advantage of providing quick-turn terminal sterilization with simple, clean, on/off technology. There is no carcinogenic gas/radioactive source needed, and there are no residuals, so the product can be immediately released for distribution. Due to the growing applications of E-beam and its increasing uptake among different end-user segments, the market for e-beam sterilization is expected to witness significant growth during the forecast period. E-beam sterilization offers several advantages over other methods of sterilization. Using e-beam, products can be irradiated for only a few seconds and, therefore, may not be subject to radiation incompatibility, sometimes seen with gamma irradiation and ethylene oxide (EtO) sterilization. Moreover, the overall process time, inclusive of the transportation time, averages from five to seven minutes in this type of sterilization. Using established and recognized dosimetric release procedures, products can be released from quarantine as sterile within 30 minutes. While E-beam takes one minute per package for sterilization, gamma irradiation requires four to six hours, whereas EtO needs up to 14 days. Moreover, this technology can also be added to the production line. This helps in reducing distribution costs, the amount of handling, and related risks. Currently, 95% of all medical devices considered suitable for radiation sterilization can be sterilized using E-beam.

Challenge: Development of alternative technologies for surface disinfection
Many new technologies are being developed and tested as an alternative to the current methods of surface disinfection, which are manual in nature. These include:
• Electrolyzed water (Hypochlorous acid)
• Cold atmospheric pressure plasma
• Self-disinfecting surfaces
• No-touch decontamination such as aerosol, vaporized hydrogen peroxide, and pulsed xenon UV light systems
• Cold air atmospheric plasma

These technologies are in different stages of development and testing and show promising results. For example, in laboratory studies, the reactive oxygen species generated by cold air atmospheric systems have shown bactericidal activity against a variety of pathogens, with variable activity against C. difficile spores. One group of investigators found that electrolyzed water effectively reduced the number of aerobic bacteria (including staphylococci) on near-patient surfaces, but for reasons not well understood, it appeared to allow the regrowth of staphylococci within 24 hours of application. Electrolyzed water does not leave toxic residues on surfaces after its usage. Although commercializing such technologies will be challenging and cost-intensive, they do provide possible alternatives. In the coming years, post-commercialization, these technologies will pose a major challenge to the growth of traditional methods of surface disinfection, such as the use of liquids and sprays.

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1084

Key Market Players
The prominent players in this market are STERIS plc. (US),Getinge AB (Sweden), Cantel Medical Corporation (US), Advanced Sterilization Products (US), 3M Company (US), Belimed AG (Switzerland), MMM Group (Germany), MATACHANA GROUP (Spain), Sotera Health LLC (US), Ecolab, Inc. (US), Metrex Research Corporation (US), Reckitt Benckiser Group Plc. (UK), Miele Group (Germany), Melag (Germany), and Pal International (UK).

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441